BioMarin’s Orphan Drug Clinical Strategy Is Rooted In Natural History
This article was originally published in Pharmaceutical Approvals Monthly
BioMarin has emerged at the forefront of orphan drug development by grounding its clinical trials in natural history studies. The specialty firm’s recent investor day highlighted how clinical trials in ultra-orphan disorders are informed by efforts to quantify the clinical course of often poorly-understood conditions to determine appropriate endpoints and dosing strategies.
You may also be interested in...
Baby Steps To Real-World Evidence Of Efficacy: External Controls Gain Popularity In Rare Disease Trials
The Pink Sheet takes a closer look at recent clinical announcements showing how rare disease therapy sponsors are already increasingly reliant on natural history studies to guide drug development.
FDA Orphan Approval Flexibility Remains Steady As Pressure Increases
Frank Sasinowski updates his 2012 landmark analysis and finds that FDA maintained its rate of flexibility in the evidentiary standards for approval of orphan products.
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a Pink Sheet analysis of FDA approval decisions since 2021.